Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia Hikma Rejected Dasatinib 2 LPI-JOR-LEB-KSA-TUN- KFSH & RC - R
"Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients " Astellas Completed Micafungin 3b 9463EC0001 NGHA-R
"Randomized, Embedded, Multifactorial Adaptive Platform trial for Community- Acquired Pneumonia (REMAP-CAP)" KAIMRC Ongoing Ceftriaxone - Piperacillin Tazobactam - Azithromycin - Interferon β1-a - Hydrocortisone sodium suc... - Hydroxychloroquine - OSELTAMIVIR - Lopinavir-Ritonavir 3 CT20/001/R NGHA-R
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition. SPIMACO ADDWAEIH Ongoing solifenacin succinate 1, BE 42767 Saudi Ajal
Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy subjects under fasting condition. MEDIS Laboratories Ongoing Enoxa / Enoxaparin 3, BE 21-2017 Saudi Ajal
Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions. MEDIS Laboratories Ongoing Tacrolimus/ Prograf 1, BE 19-2017 Saudi Ajal
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma King Faisal Specialist Hospital and Research Centre Ongoing Sorafenib (Nexavar) 3 RTOG 1112 KFSH & RC-R
"Randomized clinical trial of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients" King Abdullah Medical City Ongoing DENOSUMAB 3 20-610 King Abdullah Medical City (Makkah)
"randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)" GSK Completed Ambrisentan 5 mg 3 AMB115811 KFMC
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity Novartis Ongoing Ranibizumab 3 CRFB002H2301 V 01 KFSH & RC-R
View 191 - 200 From 741